In the News
Sep 19, 2014
In the News
Friends say Andrea Sloan would have loved to attend a summit this weekend in Washington, D.C., that will focus on research for childhood cancer and expanded access to experimental drugs for all cancer patients.
Sloan, 45, passed away earlier this year after a fight to gain access to an experimental drug to treat her ovarian cancer through a process called compassionate use. She was eventually granted access to a different drug made by a different company, but by then, her cancer had progressed too far.
Issues:
Jul 31, 2014
In the News
Regeneron Pharmaceuticals Inc. and Sanofi SA are spending $67.5 million on a novel bet they hope will help them outflank Amgen Inc. in the race to get a new class of cholesterol drugs to the market.
The companies are paying the money to acquire a special voucher held by BioMarin Pharmaceuticals Inc. in a bid to hasten regulatory review of their drug alirocumab, one of an emerging group of medicines that lower cholesterol by targeting a gene known as PCSK9.
Issues: